Compass Therapeutics

Compass Therapeutics Goodwill

Goodwill of Compass Therapeutics (CMPX) as of Oct 16, 2026.

Goodwill

-USD

Last updated:

Goodwill of Compass Therapeutics is 2026 - USD. Goodwill of Compass Therapeutics was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Compass Therapeutics Stock analysis

What does Compass Therapeutics do? Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts. The company has 39 employees and went public on November 13, 2020. Compass Therapeutics focuses on developing proprietary antibody therapeutics for multiple human diseases. Its pipeline includes three product candidates: CTX-009, CTX-471, and CTX-8371. CTX-009 is a bispecific antibody targeting DLL4 and VEGF-A. CTX-471 is an agonistic antibody targeting CD-137. CTX-8371 is a bispecific antibody targeting PD-1 and PD-L1. Compass Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Compass Therapeutics stock

On Eulerpool you can find the complete historical development of Goodwill Compass Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Compass Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Compass Therapeutics

All Key Metrics — Compass Therapeutics